Condition: Solid Tumor · Small Cell Lung Cancer (SCLC) · High Grade Neuroendocrine Cancer · Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
This description comes directly from the study's public registry record.
Exscientia AI Ltd. · 385-374-1724 · clinicaltrials@recursion.com
Always discuss trial participation with your own doctor first.
| Start Lacn | Los Angeles, California, United States | Recruiting |
| START Dallas | Fort Worth, Texas, United States | Recruiting |
| START Mountain Region | West Valley City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07517198